Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.68 |
| ▸ | PLK1 | P53350 | 18/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 12/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.44 |
| ▸ | TAF1 | P21675 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384394 | 1.00 | BRD4 (0.68) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL382638 | 0.92 | BRD4 (0.68) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL1288316 | 0.92 | BRD4 (0.68) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL1288315 | 0.92 | BRD4 (0.68) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL382639 | 0.92 | BRD4 (0.68) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL384196 | 0.90 | BRD4 (0.66) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL2952174 | 0.90 | BRD4 (0.66) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL384195 | 0.90 | BRD4 (0.66) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL2952170 | 0.90 | BRD4 (0.66) | BRD4PLK1PLK2PLK3TAF1 | |
| SCHEMBL10093332 | 0.86 | BRD4 (0.67) | BRD4PLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-8637666-B2 | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637666-B2 | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8524902-B2 | [1,2,4]triazolo[4,3-f]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524902-B2 | [1,2,4]triazolo[4,3-f]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524902-B2 | [1,2,4]triazolo[4,3-f]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-01 | — | — | US | disclosed |
| US-8067417-B2 | Imidazo[1,2-F]pteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277425-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKCH, DMPK, MAP3K20 | BRD4 1254/4885PLK1 159/4885PLK2 260/4885 |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | PRKCH, DMPK, MAP3K20 | BRD4 1254/4885PLK1 159/4885PLK2 260/4885 |
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | CDK20, CDK10, MAPK1 | BRD4 2844/4885PLK1 92/4885PLK2 99/4885 |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKCH, DMPK, MAP3K20 | BRD4 1254/4885PLK1 159/4885PLK2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.